Emerald Mutual Fund Advisers Trust Takes Position in OncoCyte Corp (OCX)

Emerald Mutual Fund Advisers Trust acquired a new stake in OncoCyte Corp (NYSEAMERICAN:OCX) in the first quarter, Holdings Channel reports. The firm acquired 2,490,000 shares of the biotechnology company’s stock, valued at approximately $9,836,000.

Several other large investors have also recently bought and sold shares of OCX. Virtu Financial LLC acquired a new position in shares of OncoCyte in the first quarter valued at approximately $114,000. Perkins Capital Management Inc. acquired a new position in shares of OncoCyte in the first quarter valued at approximately $99,000. Finally, Vanguard Group Inc raised its position in shares of OncoCyte by 3.8% in the third quarter. Vanguard Group Inc now owns 410,275 shares of the biotechnology company’s stock valued at $1,026,000 after buying an additional 15,115 shares during the last quarter.

Shares of OCX stock opened at $4.39 on Monday. OncoCyte Corp has a one year low of $1.16 and a one year high of $6.92.

OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings results on Monday, April 1st. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02).

Several equities analysts recently commented on OCX shares. Zacks Investment Research lowered shares of OncoCyte from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Chardan Capital reaffirmed a “buy” rating and set a $8.00 price target on shares of OncoCyte in a research report on Tuesday, April 2nd. Lake Street Capital upped their price target on shares of OncoCyte from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 29th. Piper Jaffray Companies started coverage on shares of OncoCyte in a research report on Wednesday, February 13th. They set an “overweight” rating and a $6.00 price target for the company. Finally, Janney Montgomery Scott raised shares of OncoCyte from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 29th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.95.

TRADEMARK VIOLATION NOTICE: This article was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/13/emerald-mutual-fund-advisers-trust-takes-position-in-oncocyte-corp-ocx.html.

OncoCyte Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Read More: What is a resistance level?

Want to see what other hedge funds are holding OCX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OncoCyte Corp (NYSEAMERICAN:OCX).

Institutional Ownership by Quarter for OncoCyte (NYSEAMERICAN:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.